ALXN Alexion Pharmaceuticals Inc.

132.94
-0.57  -0%
Previous Close 133.51
Open 133.57
Price To Book 3.24
Market Cap 29708019510
Shares 223,469,381
Volume 1,001,028
Short Ratio
Av. Daily Volume 1,627,048

NewsSee all news

  1. Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
  2. Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
  3. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  4. Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript
  5. If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 28, 2019.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 data released January 28, 2019. Primary endpoint met. Regulatory filing due 1H 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 trial is enrolling.
WTX101
Wilson disease
Phase 3 trial to be initiated 1Q 2019.
ULTOMIRIS (ravulizumab-cwvz)
Generalized myasthenia gravis (gMG)
Phase 1b/2a trial to be completed in 2019 with two pivotal trials to follow.
ALXN1830
Warm autoimmune hemolytic anemia (WAIHA)
Phase 3 PK data due early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)

Latest News

  1. Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
  2. Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
  3. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  4. Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript
  5. If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today
  6. Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve
  7. Why Is Alexion (ALXN) Up 9.7% Since Last Earnings Report?
  8. Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions — Research Highlights Growth, Revenue, and Consolidated Results
  9. Mass. life science leaders say outgoing FDA head was an 'advocate for modernization'
  10. Alexion to Present at the Cowen 39th Annual Health Care Conference
  11. Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials
  12. These 10 New Drugs Expected In 2019 Are On The Blockbuster Track
  13. Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
  14. America's 'inefficient' health care system is driving our fiscal instability: Powell
  15. 5 Clinical-Stage Biotech Stocks to Buy
  16. FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  17. Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  18. Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4
  19. IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range